Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924273 · ClinicalTrials.gov registry record · Phase 1
Novel Treatment for Port Wine Stain Birthmarks
A Phase 1 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01924273 is a Phase 1 study that has completed, run by University of California, Irvine. The registered enrollment target is 7 participants.
The verdict
NCT01924273, a Phase 1 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Port wine stains Birthmark are congenital, progressive vascular malformations of the skin that occur in approximately 0.7% of newborns. Approximately 1.5 million individuals in the United States and 32 million people worldwide have Port wine stains birthmarks. Two-thirds of these malformations occur on the face. Personality development of virtually all patients is adversely affected as a result of the negative reaction of others to a "marked" person. Detailed studies have documented lower self-esteem and difficulties with interpersonal interactions in Port wine stains patients. Port wine stains are initially flat and red, but with time, they tend to darken to purple and become thickened as vascular nodules develop. This thickening occurs in approximately two-thirds of lesions and further disfigures the facial features of many patients.
Interventions
- DRUG Talaporfin sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-06 |
| Est. Completion | 2017-07-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924273
The ClinicalTrials.gov registry entry for NCT01924273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Talaporfin sodium is the first listed.
NCT01924273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01924273 about?
NCT01924273 is a clinical study titled "Novel Treatment for Port Wine Stain Birthmarks". Port wine stains Birthmark are congenital, progressive vascular malformations of the skin that occur in approximately 0.7% of newborns. Approximately 1.5 million individuals in the United States and 32 million people worldwide have Port wine stains birthmarks. Two-thirds of these malformations occur...
What is the current status of trial NCT01924273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2013-06. Estimated completion is 2017-07-03.
What interventions are being tested in trial NCT01924273?
The interventions under investigation include: Talaporfin sodium (DRUG).
Who is sponsoring clinical trial NCT01924273?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.